



European  
Investment Bank

# **AMR One Health Network**

## **February 29, 2024, Brussels**

*Head of Life Sciences & Health Division (LSH)*  
*European Investment Bank*

# THE EIB AT A GLANCE

## Improving quality of life in Europe and beyond



### The world's largest multilateral lender

We raise our funds on the international capital markets  
We pass on favourable borrowing conditions



### Governed by the EU Member States

Shareholders are the EU 27 Member States



### Headquartered in Luxembourg

Around 3 400 staff in 50 global offices



### Leading provider of climate finance

€ 36.5 bn in climate action investments in 2022



### In 60 years, over €1.2 trillion invested

More than 12 000 projects in over 160 countries  
Crowding-in bank: €3 trillion investment mobilised



€ 72.45 billion in financing in 2022

## Our Priorities

### INNOVATION, DIGITAL AND HUMAN CAPITAL



€ 17.93 Bn

### SUSTAINABLE ENERGY AND NATURAL RESOURCES



€ 20.86 Bn

### SUSTAINABLE CITIES AND REGIONS



€ 17.31 Bn

### SMES AND MID CAPS




€ 16.35 Bn




# EIB E&S STANDARDS



# ONE HEALTH REQUIRES A HOLISTIC INVESTMENT STRATEGY APPROACH



# GREEN INVESTMENTS: €36.5 BILLION IN 2022



\* Total dual benefit contributing to both climate action and environmental sustainability objectives reached €14.3 billion.

Social & Economic  
Instability

## EIB LEADING SUSTAINABLE INVESTMENT



In 2018, the EIB issued its inaugural Sustainability Awareness Bond (SAB), extending its established allocation and reporting practice to cover the **full spectrum of sustainability**.




In 2007, the EIB issued its inaugural Climate Awareness Bond (CAB), **the world's first green bond**. CABs provide **clarity and accountability** through their dedicated use-of-proceeds.





# The share of CAB/SAB issuance in EIB's total funding programme is growing



**Total CAB/SAB issued: EUR 68bn**  
**Total CAB/SAB outstanding: EUR 59bn**  
**Number of CAB/SAB currencies: 22**

**Issuance of EUR 4bn CAB EARN due 2032 and USD 4bn SAB Global due 2027**

\*CAB ELIGIBILITIES: CAB (left axis) SAB (left axis) CAB & SAB share (right axis)

**2007-2020:** RE&EE projects; **2020:** Extended to: (a) Electric rail infrastructure and vehicles and other electric public land transport vehicles, (b) Research, development and deployment of innovative low carbon technologies.


\*SAB ELIGIBILITIES: **2018-2020:** Water projects; **2020:** Extended to Education and Health projects (incl. COVID-19); **2021:** Extended to Forestry and Housing Projects

\*\*Data as of September 2022  
 Source: EIB Sustainability Funding Team



- INNOVATION
- BEST AVAILABLE TECHNIQUES (BAT)
- INTEGRATED APPROACH

# OVER THE PAST 20 YEARS, THE EIB HAS LENT OVER EUR 49 BILLION TO THE LIFE SCIENCE AND HEALTH SECTOR



- Health care sector projects (mainly infrastructure)
- Life sciences projects (mainly innovation)

Source: EIB / PJ Statistics and Reporting, 2023





- INNOVATION
- BEST AVAILABLE TECHNIQUES (BAT)
- INTEGRATED APPROACH

# AMR FUND



## The Problem



## Part of the Solution



An initiative from over 20 leading biopharmaceutical companies that have pledged to invest nearly **USD 1 billion**, with the aim to bring 2-4 new antibiotics to market by 2030.

The concept of the AMR Action Fund was developed by the [IFPMA](#) and the Biopharmaceutical CEOs Roundtable ([BCR](#)), in collaboration with the World Health Organization (WHO), the EIB, and the Wellcome Trust.

## EQUITY OF ACCESS TO CARE – AN IMPORTANT FACTOR

Healthcare systems should meet the fundamental principle of  
SOCIAL SOLIDARITY:

the **whole population** should have **equal access** to a reasonable range of drugs and standard of health care irrespective of their ability to pay for health care.



Universal Health Coverage


# OUR EXTERNAL PARTNERS

*Fostering Sustainable Health for All*





# Case Studies



## ANIMAL HEALTH R&D (SPAIN)

*Signed 2019*



EUR 35 million to finance the development of new proprietary vaccines to prevent diseases in animals, both food production and companion animals.



Hipra is engaged in the animal health business, developing, manufacturing and commercialising vaccines and pharmaceutical products across seven core animal species: swine, cattle, poultry, sheep & goats, rabbits, dogs and fish. Complementary businesses include vaccination devices, diagnostic kits for veterinary professionals, as well as expert customer service and technical education.



Hipra's R&D efforts will generate a robust portfolio of next generation, innovative products addressing global animal health issues, a key driver for organic growth and international expansion. Hipra is one of the leading companies in the veterinary market, and through this project, it will enhance Europe's leadership position in the animal health industry.

# FRENCH ANIMAL HEALTH R&D INVESTMENTS (FRANCE)

*Signed 2017*



EUR 80 million to finance the promoter's R&D expenditures, over the years 2017-2020 to support the development of the ongoing projects within the R&D portfolio of the company such as: novel vaccines (e.g. respiratory vaccine for dogs), antibiotics substitutes (Aminosterol Derivatives), novel formulations for an oral administration of Metronidazole palatable (Gastrointestinal and anti-infective) and more.



Virbac S.A., the 7<sup>th</sup> largest pharmaceutical veterinary company globally, founded in 1968 by the veterinarian Pierre-Richard Dick, is a French company dedicated to animal health headquartered in Carros, France. The company operates on both major animal health market segments, i.e. Companion Animals and Food Producing Animals. Virbac's innovation offers a range of products and services covering the majority of species and pathologies in more than 100 countries.




Support the promoter's R&D efforts to generate a robust portfolio of next generation, innovative products, addressing global animal health issues, a key driver for organic growth and international expansion. Through its R&D activities, the company is expected to contribute to the competitive search for, and generation of, new knowledge in Europe in areas that are important for the improvement of the health of its citizens, given the strong interplay between animal health and human health.



# F2G ANTIFUNGAL AGENT (IDFF) (AUSTRIA, UNITED KINGDOM)

*Signed 2018*



EUR 24 million to finance F2G's research and development (R&D) activities focused on the development of Olorofim and other compounds to treat fungal infections. The project will be managed from the company's headquarters located in Vienna, Austria and in Manchester, United Kingdom.



F2G is an established biotech company, which was originally incorporated in 1998 in Manchester as a spin-out from Manchester University and has since also set up a subsidiary in Austria. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity.



The lead programme addresses Invasive Aspergillosis (IA) with a new mechanism of action. In doing so, the project is fully in line with the objectives of InnovFin IDFF. It would also be the first project under IDFF addressing a fungal infection (all other projects addressed bacterial or viral infections). Contributes to combatting Antimicrobial Resistance (AMR). Aspergillosis is a severe and life-threatening mold infection occurring in immuno-compromised patients which if left untreated has a mortality rate exceeding 95%. Therefore, it represents a significant unmet medical need which the project will address.

# MINERVAX (IDFF) (DENMARK)

Signed 2022



EUR 50 million to finance MinervaX, a Danish biotechnology company developing a novel, protein-based vaccine against Group B Streptococcus (GBS).



The project financing will enable MinervaX to advance the late-stage development of its GBS vaccine candidate, which has the potential to prevent life-threatening infections and harmful pregnancy outcomes in newborn babies caused by GBS transmission during delivery.



GBS is a major contributor to life-threatening infections in newborns. GBS is recognised as a concerning threat due to issues of antimicrobial resistance and interspecies transmission. Between 15% to 25% of women worldwide are infected with GBS, posing a risk of transmission to their infants during pregnancy, birth, or early infancy. GBS infections can result in adverse outcomes such as late-term abortions, premature delivery, stillbirth, leading to significant morbidity, long-term disability, or death.

THANK YOU!

ANY QUESTIONS?

